Piramal Pharma is currently trading at Rs. 160.50, up by 10.20 points or 6.79% from its previous closing of Rs. 150.30 on the BSE.
The scrip opened at Rs. 157.25 and has touched a high and low of Rs. 166.60 and Rs. 155.30 respectively. So far 1224481 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 166.60 on 13-May-2024 and a 52 week low of Rs. 69.91 on 19-May-2023.
Last one week high and low of the scrip stood at Rs. 166.60 and Rs. 144.00 respectively. The current market cap of the company is Rs. 21233.32 crore.
The promoters holding in the company stood at 35.02%, while Institutions and Non-Institutions held 42.71% and 22.26% respectively.
Piramal Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2024.
The company has reported over 6-fold jump in its net profit at Rs 273.08 crore for the quarter under review as compared to Rs 41.70 crore for the same quarter in the previous year. Total income of the company increased by 41.26% at Rs 1,578.49 crore for Q4FY24 as compared Rs 1,117.46 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 2-fold jump in its net profit at Rs 101.27 crore for fourth quarter ended March 31, 2024 as compared to Rs 50.11 crore for the same quarter in the previous year. Total income of the company increased by 17.85% at Rs 2,578.74 crore for Q4FY24 as compared Rs 2,188.08 crore for the corresponding quarter previous year.
For the year ended March 31, 2024, the company has reported over 5-fold jump in net profit at Rs 391.22 crore as compared to Rs 69.50 crore for the previous year. Total income of the company increased by 21.35% at Rs 4,592.17 crore for year under review as compared to Rs 3,784.29 crore for year ended March 31, 2023.
For the year ended March 31, 2024, on the consolidated basis, the company has reported net profit at Rs 17.82 crore as compared to net loss of Rs 186.46 crore for the previous year. Total income of the company increased by 14.23% at Rs 8,346.55 crore for year under review as compared to Rs 7,306.66 crore for year ended March 31, 2023.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1462.50 |
| Dr. Reddys Lab | 5784.50 |
| Cipla | 1451.25 |
| Zydus Lifesciences | 1001.15 |
| Lupin | 1587.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
